No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer by Hollestelle, Antoinette et al.
No clinical utility of KRAS variant
rs61764370 for ovarian or breast cancer
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Hollestelle, Antoinette, Frederieke H. van der Baan, Andrew
Berchuck, Sharon E. Johnatty, Katja K. Aben, Bjarni A. Agnarsson,
Kristiina Aittomäki, et al. 2016. “No Clinical Utility of KRAS Variant
Rs61764370 for Ovarian or Breast Cancer.” Gynecologic Oncology
141 (2) (May): 386–401. doi:10.1016/j.ygyno.2015.04.034.
Published Version doi:10.1016/j.ygyno.2015.04.034
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:33840791
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Open Access Policy Articles, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#OAP
No clinical utility of KRAS variant rs61764370 for ovarian or 
breast cancer
A full list of authors and affiliations appears at the end of the article.
Abstract
Objective—Clinical genetic testing is commercially available for rs61764370, an inherited 
variant residing in a KRAS 3′ UTR microRNA binding site, based on suggested associations with 
increased ovarian and breast cancer risk as well as with survival time. However, prior studies, 
emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated 
ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.
Methods—Centralized genotyping and analysis were performed for 140,012 women enrolled in 
the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the 
Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the 
Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation 
carriers).
Results—We found no association with risk of ovarian cancer (OR= 0.99, 95% CI 0.94–1.04,p = 
0.74) or breast cancer (OR = 0.98, 95% CI 0.94–1.01, p = 0.19) and results were consistent among 
mutation carriers (BRCA1, ovarian cancer HR = 1.09, 95% CI 0.97–1.23, p = 0.14, breast cancer 
HR = 1.04, 95% CI 0.97–1.12, p = 0.27; BRCA2, ovarian cancer HR = 0.89, 95% CI 0.71–1.13, p 
= 0.34, breast cancer HR = 1.06, 95% CI 0.94–1.19, p = 0.35). Null results were also obtained for 
associations with overall survival following ovarian cancer (HR = 0.94, 95% CI 0.83–1.07, p = 
0.38), breast cancer (HR = 0.96, 95% CI 0.87–1.06, p = 0.38), and all other previously-reported 
associations.
Conclusions—rs61764370 is not associated with risk of ovarian or breast cancer nor with 
clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical 
utility related to the prediction or management of these cancers.
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1. Introduction
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that negatively 
regulate gene expression by binding partially complementary sites in the 3′ untranslated 
regions (UTRs) of their target mRNAs. In this way, miRNAs control many cancer-related 
biological pathways involved in cell proliferation, differentiation, and apoptosis [1]. To date, 
several inherited variants in microRNAs or miRNA target sites have been reported to confer 
increased cancer risks [2]. One such variant is located in the 3′ UTR of the KRAS gene 
(rs61764370 T > G) for which the rarer G allele has been reported to confer an increased 
risk of ovarian, breast, and lung cancer [3–7] as well as endometriosis [8], although not 
consistently [9–11].
For ovarian cancer, the rs61764370 G allele was also reported to be associated with 
increased risk (320 cases, 328 controls). Further increased risks were observed among 23 
BRCA1 mutation carriers and 31 women with familial ovarian cancer, but without BRCA1 
or BRCA2 mutations [3]. In contrast, no association with ovarian cancer risk was seen in 
another, much larger study, based on 8669 cases, 10,012 controls, and 2682 BRCA1 
mutation carriers [9]. One criticism on the latter study was that some of the genotype data 
were for rs17388148, an imputed proxy for rs61764370; even though rs17388148 is highly 
correlated with rs61764370 (r2 = 0.97) and was imputed with high accuracy (r2 = 0.977) 
[12,13]. The minor allele of rs61764370 was also associated with shorter survival time in a 
study of 279 ovarian cancer patients diagnosed after age 52 years with platinum-resistant 
disease (28 resistant, 263 not resistant) and with sub-optimal debulking surgery after 
neoadjuvant chemotherapy (7 sub-optimal, 109 optimal) [14]. However, another study 
observed no association between rs61764370 and ovarian cancer outcome (329 cases) [15].
For breast cancer, a borderline significant increased frequency of the rs61764370 G allele 
was observed in 268 BRCA1 mutation carriers with breast cancer, but not in 127 estrogen 
receptor (ER)-negative familial non-BRCA1/BRCA2 breast cancer patients [5]. However, in 
a subsequent study, the variant was reported to be associated with increased risk of ER/PR 
negative disease (80 cases, 470 controls), as well as with triple negative breast cancer 
diagnosed before age 52 (111 cases, 250 controls), regardless of BRCA1 mutation status [6]. 
The validity of these findings has been questioned given the very small sample sizes and the 
number of subgroups tested [16,17]. Another report found no association with sporadic or 
familial breast cancer risk (695 combined cases, 270 controls), but found that the variant was 
associated with ERBB2-positive and high grade disease, based on 153 cases who used post-
menopausal hormone replacement therapy [18].
It has also been reported, based on 232 women with both primary ovarian and breast cancer, 
that the frequency of the G allele at rs61764370 was increased for those who were screened 
negative for BRCA1 and BRCA2 (92 cases), particularly among those enrolled within two 
years of their ovarian cancer diagnosis (to minimize survival bias, 30 cases), those diagnosed 
with post-menopausal ovarian cancer (63 cases), those with a family history of ovarian or 
breast cancer (24 cases), and those with a third primary cancer (16 cases) [4].
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This notable lack of consistency in findings between studies might be expected when 
appropriate levels of statistical significance are not used to declare positive findings from 
multiple small subgroup comparisons or post-hoc hypotheses [19]. In this respect, the 
dangers of subgroup analyses in the context of clinical trials are well-recognized [20]. These 
are important caveats, particularly since a genetic test for rs61764370 is currently marketed 
in the US for risk prediction testing to women who are at increased risk for developing 
ovarian and/or breast cancer or women who have been diagnosed with either ovarian or 
breast cancer themselves [21]. In general, much larger studies, with sufficient power to 
detect positive findings at much more stringent levels of statistical significance ought to be 
required to establish the clinical validity of a genetic test. Therefore, we conducted 
centralized genotyping of rs61764370 and other variants in the genomic region around the 
KRAS gene in 140,012 women to examine associations with risk and clinical outcome of 
ovarian and breast cancer.
2. Methods
2.1. Study participants
The following three consortia contributed to these analyses: the Ovarian Cancer Association 
Consortium (OCAC:41 studies, Supplementary Table S1) [22], the Breast Cancer 
Association Consortium (BCAC: 37 studies, Supplementary Table S2) [23], and the 
Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA: 55 studies, Supplementary Table 
S3) [24,25]. OCAC and BCAC consisted of case–control studies of unrelated women, and 
CIMBA consisted of studies of women with germline deleterious BRCA1 or BRCA2 
mutations primarily identified through clinical genetics centers. For the purpose of the 
current analyses, only participants of European ancestry were included. Following 
genotyping, quality control exclusions (described below), and analysis-specific exclusions, 
data from the following women were available for analysis: 46,173 OCAC participants 
(15,357 patients with invasive epithelial ovarian cancer and 30,816 controls), 71,170 BCAC 
participants (33,530 patients with invasive breast cancer and 37,640 controls), and 22,669 
CIMBA participants (for ovarian cancer analyses: 2332 affected and 12,433 unaffected 
BRCA1 carriers, 599 affected and 7305 unaffected BRCA2 carriers; for breast cancer 
analyses: 7543 affected and 7222 unaffected BRCA1 carriers, 4138 affected and 3766 
unaffected BRCA2 carriers). For OCAC, overall and progression-free survival data were 
available for 3096 patients from 13 studies. Overall survival data were available for 28,471 
patients from 26 BCAC studies and for 2623 mutation carriers with breast cancer from 11 
CIMBA studies (excluding studies with less than ten deaths) as described previously [26,27]. 
Each study was approved by its relevant governing research ethics committee, and all study 
participants provided written informed consent.
2.2. Genotyping and imputation
Genotyping for rs61764370 was performed using the custom iCOGS Illumina Infinium 
iSelect BeadChip, as previously described [22–25]. In total, DNA from 185,443 women of 
varying ethnic background was genotyped (47,630 OCAC participants, 114,255 BCAC 
participants, 23,558 CIMBA participants), along with HapMap2 DNAs for European, 
African, and Asian populations. Genotype data were also available for three OCAC genome-
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wide association studies (UK GWAS, US GWAS, Mayo GWAS) that had been genotyped 
using either the Illumina Human610-Quad Beadchip (12,607 participants) [28] or the 
Illumina HumanOmni2.5–8 Beadchip (883 participants). Raw intensity data files underwent 
centralized genotype calling and quality control [22–25]. HapMap2 samples were used to 
identify women with predicted European intercontinental ancestry; among these women, a 
set of over 37,000 unlinked markers was used to perform principal component (PC) analysis 
[29]. The first five and seven European PCs were found to control adequately for residual 
population stratification in OCAC and BCAC data, respectively. Samples with low 
conversion rate, extreme heterozygosity, non-female sex, or one of a first-degree relative pair 
(the latter for OCAC and BCAC only) were excluded. Variants were excluded if they were 
monomorphic or had a call rate <95% (minor allele frequency (MAF) >0.05) or <99% 
(MAF <0.05), deviation from Hardy–Weinberg equilibrium (p< 10−7),or >2%duplicate 
discordance.
In addition to rs61764370, 54 variants within 100 kb on either side of KRAS on 
chromosome 12 (25,258,179 to 25,503,854 bp in GRCh37.p12) were genotyped. Moreover, 
to provide a common set of variants across the region for analysis in all the data sets, we also 
used imputation to infer genotypes for another 1056 variants and for variants that failed 
genotyping. We performed imputation separately for OCAC samples, BCAC samples, 
BRCA1 mutation carriers, BRCA2 mutation carriers, and for each of the OCAC GWAS. We 
imputed variants from the 1000 Genomes Project data using the v3 April 2012 release as the 
reference panel [30]. To improve computation efficiency we initially used a two-step 
procedure, which involved pre-phasing using the SHAPEIT software [31] in the first step 
and imputation of the phased data in the second. We used the IMPUTE version 2 software 
[32]for the imputation for all studies with the exception of the US GWAS for which we used 
the MACH algorithm implemented in the minimac software version 2012.8.15 and MACH 
version 1.0.18 [33]. We excluded variants from association analyses if their imputation 
accuracy was r2 < 0.30 or their MAF was <0.005, resulting in 974 variants genotyped and 
imputed for OCAC, 989 variants genotyped and imputed for BCAC, and 1001 variants 
genotyped and imputed for CIMBA, including rs61764370 (Supplementary Tables S5, S6, 
and S7).
2.3. Analysis
Genotypes were coded for genotype dosage as 0,1, or 2, based on the number of copies of 
the minor allele. For ovarian cancer case–control analysis (i.e., OCAC studies), logistic 
regression provided estimated risks of invasive epithelial ovarian cancer with odds ratios 
(ORs) and 95% confidence intervals (CIs) adjusting for study, age, and the five European 
PCs. Subgroup analyses were conducted by histology, family ovarian and breast cancer 
history, menopausal status, time between ovarian cancer diagnosis and recruitment, and 
history of multiple primary cancers. For breast cancer case–control analysis (i.e., BCAC 
studies), the association between genotype and invasive breast cancer risk was evaluated by 
logistic regression, adjusting for study, age, and the seven European PCs, providing ORs and 
95% CIs. Additional subgroup analyses were based on receptor status, first-degree family 
ovarian and breast cancer history, BRCA1 and BRCA2 mutation status, enrollment within 
two years of diagnosis, menopausal status (i.e. last menstruation longer than twelve months 
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ago), age at diagnosis less than 52 years, and history of hormone replacement therapy use 
(i.e. longer than twelve months use). Risk analysis for BRCA1 and BRCA2 mutation 
carriers (i.e. CIMBA studies) was done using a Cox proportional hazard model to estimate 
hazard ratios (HRs) per copy of the minor allele, with age as follow-up time and stratified by 
country of residence; US and Canadian strata were further subdivided by self-reported 
Ashkenazi Jewish ancestry [24,25]. A weighted cohort approach was applied to correct for 
potential testing bias due to overrepresentation of cases in the study population [34]. We 
used robust variance estimation to allow for the non-independence of carriers within the 
same family [35]. To assess associations with ovarian cancer risk, mutation carriers were 
followed from birth until ovarian cancer diagnosis (event), a risk-reducing salpingo-
oophorectomy (RRSO) or the age at enrollment, whichever occurred first. We also 
performed analyses restricted to women diagnosed or censored within two years before their 
enrollment. To assess associations with breast cancer risk, mutation carriers were followed 
from birth until a breast cancer diagnosis (i.e. either ductal carcinoma in situ or invasive 
breast cancer), ovarian cancer diagnosis, a risk-reducing bilateral prophylactic mastectomy 
or the age at enrollment, whichever occurred first.
Survival analysis of OCAC patients used Cox proportional hazards models estimating HRs 
and 95% CIs considering overall survival as well as progression-free survival following 
ovarian cancer diagnosis. Overall survival was adjusted for age at diagnosis, the five 
European PCs, histology, grade, FIGO stage, and residual disease after debulking surgery, 
and stratified by study, left truncating at the date of study entry and right censoring at five 
years to minimize events due to other causes. Progression-free survival was analyzed as for 
overall survival, but without adjustment for age and right censoring, and was defined as the 
time between the date of histologic diagnosis and the first confirmed sign of disease 
recurrence or progression, based on GCIG (Gynecological Cancer InterGroup) criteria [36]. 
We also performed subgroup analysis of patients suboptimally debulked after cytoreductive 
surgery (residual disease >1 cm) and of post-menopausal patients (age at diagnosis >52 
years). Survival analysis of BCAC patients used Cox proportional hazard models estimating 
HRs and 95% CIs considering overall and breast cancer-specific survival following breast 
cancer diagnosis. Models were adjusted for age at diagnosis, tumor size, nodal status, grade, 
adjuvant hormonal and/or chemotherapy, and stratified by study, left-truncating at the date of 
study entry and right censoring at ten years. In addition, we performed subgroup analysis on 
ER-positive and ER-negative patients. For CIMBA breast cancer patients associations 
between genotype and overall survival were evaluated using Cox proportional hazard models 
estimating HRs and 95% CIs. Models were adjusted for age at diagnosis, tumor size, nodal 
status, grade, adjuvant hormonal and/or chemotherapy, and preventive bilateral 
oophorectomy and stratified by study, left-truncating at the date of study entry and right 
censoring at twenty years. Analyses were performed using STATA version 12.0 (StataCorp, 
Texas, USA).
3. Results
The results of the overall analysis as well as the subgroup analyses investigating the 
association between the minor allele at rs61764370 and ovarian cancer risk, breast cancer 
risk, and ovarian and breast cancer risks in BRCA1 and BRCA2 mutation carriers are shown 
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in Table 1. Associations with clinical outcomes in and ovarian and breast cancer patients 
including BRCA1 and BRCA2 mutation carriers are shown in Table 2 and Supplementary 
Table S4.
We found no evidence for association between the rs61764370 Gallele and ovarian or breast 
cancer risk. The most statistically significant association was observed for risk of low-grade 
serous ovarian cancer (n = 485; OR 0.76, 95% CI 0.59–0.97, p = 0.031), but this finding was 
not significant after Bonferroni correction for multiple testing. We also evaluated the 
association for additional specific subgroups in which an association with rs61764370 had 
been reported previously [3–6]. Ovarian cancer subgroups considered BRCA1 mutation 
carriers as well as BRCA1 and BRCA2 screened-negative patients with first degree family 
histories of breast or ovarian cancer and patients who had been diagnosed with breast cancer 
before their ovarian cancer diagnoses. For breast cancer these included, among others, 
BRCA1 mutation carriers, patients diagnosed with ER- and PR-negative tumors, and 
patients diagnosed with triple negative tumors before age 52 years. Importantly, we observed 
no evidence for association of rs61764370 with any of these subgroups (detailed in Table 1), 
with all ORs close to unity and very narrow CIs including unity.
Similarly, case-only analyses did not reveal any associations between rs61764370 genotype 
and ovarian and breast cancer clinical features or outcome (Table 2 and Supplementary 
Table S4). For example, the previously reported association between rs61764370 and risk of 
ERBB2-positive and high grade breast cancer in hormone replacement therapy users [18] 
was not replicated (Supplementary Table S4), and in ovarian cancer analyses we found no 
evidence of reduced survival among patients diagnosed after age 52 years or patients with 
suboptimal debulking after cytoreductive surgery (Table 2) [14]. The G allele of rs61764370 
was also not associated with survival of breast cancer patients (Table 2).
Finally, we evaluated the association between the primary phenotypes of interest and 
common genetic variation (MAF > 0.02) in the genomic region of KRAS (i.e., within 100 kb 
on either side of the gene), using imputed and genotyped data on 974 variants for OCAC, 
989 variants for BCAC, and 1001 variants genotyped and imputed for CIMBA 
(Supplementary Tables S5, S6, and S7). We found no evidence of association for any of 
these variants, including rs61764370 and rs17388148, with these phenotypes that would 
withstand Bonferroni correction for multiple testing, as detailed in Supplementary Tables 
S5, S6, and S7 and shown in regional association plots (Fig. 1).
4. Discussion
Our analysis of 140,012 women genotyped for inherited variants in the KRAS region 
provides definitive clarification of the role of these variants in ovarian and breast cancer 
susceptibility and outcome. We have found no evidence to support an association between 
rs61764370 and ovarian or breast cancer risk, or clinical outcomes in patients with ovarian 
or breast cancer. In the absence of any association and with ORs close to unity we would not 
typically consider sub-group analyses, particularly sub-groups for which differential 
associations would not be expected to occur. However, given the previous positive 
associations reported for a myriad of different subgroups, we tested for association among 
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each of these subgroups and found no evidence to support the previously reported 
associations.
Our study has notable strengths. The vast majority (i.e. >95%) of the samples were 
genotyped using the same genotyping platform and employing a common approach to 
genotype calling and quality control; additional samples used denser arrays and nearly 
identical procedures. The very large sample sizes for all the major phenotypes of interest 
provide substantial statistical power to exclude any clinically relevant associated risks for the 
major phenotypes of interest (Fig. 2). The null results found here are thus not due to lack of 
statistical power, and this analysis also had greater than 80% power to detect association for 
most of the subgroups, although for some subgroups it was not possible to exclude modest 
risks. In contrast to the current findings, other genetic association analyses using the same 
genotyping platform and the same studies as included here have identified more than 90 
common germline variants associated with ovarian or breast cancer risk at p < 5 × 10−8 
[22,23,37]. While critiques on a previous null KRAS report have suggested that inclusion of 
male controls, use of “prevalent” cases, and reliance on a surrogate genetic variant may have 
led to falsely negative conclusions, these are not issues in the present data set. Rather, we 
demonstrate the importance of international collaboration to identify true associations as 
well as to refute false associations, an equally important objective.
The rise of individualized medicine including the use of panels of common variants to 
predict cancer risk more accurately than using family history alone holds great promise [38]. 
For example, the 31 prostate cancer susceptibility alleles confirmed as of 2011 (at p < 5 × 
10−8) can be combined to identify men in the top one percent of the risk distribution having 
a 3.2-fold increased risk [39]. Prediction has since then improved with now over 70 prostate 
cancer susceptibility alleles [40] and the utility of these genetic tests is currently under 
clinical evaluation. A similar clinical examination in ovarian and breast cancer is not far 
behind, with now over 18 and 77 confirmed susceptibility alleles, respectively, for these 
cancers [22,23]. The genotype at rs61764370, however, does not predict ovarian or breast 
cancer risk, even among particular subgroups of women or for particular subtypes of disease, 
nor is it a marker of differential outcome following diagnosis with these cancers. Therefore, 
genetic test results for rs61764370 should not be used to counsel women about their ovarian 
or breast cancer risks or outcome. Our results highlight the dangers of developing clinical 
tests without appropriate data from carefully conducted, large-scale studies to establish 
clinical validity.
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Fig. 1. 
Regional association plots for variants within the genomic region 100 kb either side of 
KRAS and risk of ovarian and breast cancer. X-axis position is referent to position (bp) on 
chromosome 12, build GRCh37.p12; yellow line indicates position of KRAS; red triangle 
indicates rs61764370. Y-axis is — log10(p-values) from association tests for risk of A) ER-
negative breast cancer, B) ER-positive breast cancer, C) breast cancer in BRCA1 mutation 
carriers, D) breast cancer in BRCA2 mutation carriers, E) epithelial ovarian cancer, F) 
epithelial ovarian cancer in BRCA1 mutation carriers, and G) epithelial ovarian cancer in 
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BRCA2 mutation carriers. (For interpretation of the references to color in this figure legend, 
the reader is referred to the web version of this article.)
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Fig. 2. 
Power curve for modest risk variants according to the total sample size. X-axis is total 
sample size for which case–control ratio is 1:1. Y-axis is the statistical power (range 0 · 5–1 · 
0) for variants given a range of risks, assuming alpha = 0 · 01 and minor allele frequency 0 · 
09.
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Table 2
Associations between KRAS rs61764370 and outcome in ovarian and breast cancer
Ovarian cancer analyses used OCAC data adjusted for age at diagnosis (overall survival only), the five 
European principal components, histology (serous, mucinous, endometrioid, clear cell, and other epithelial), 
grade (low versus high), FIGO stage (I–IV), residual disease after debulking surgery (nil versus any), and 
stratified by study; breast cancer analyses used BCAC data adjusted for age at diagnosis, tumor size, nodal 
status, grade, adjuvant hormonal and/or chemotherapy and was stratified by study; analyses for BRCA1 and 
BRCA2 mutation carriers used CIMBA data adjusted for age at diagnosis, tumor size, nodal status, grade, 
adjuvant hormonal and/or chemotherapy, and preventive bilateral oophorectomy and was stratified by study; 
95% CI, 95% confidence interval.
No. of
patients
No. of
events
Hazard ratio
(95% CI)
p-Value
Ovarian cancer
Overall survival
  All patients 3096 1421 0.94 (0.83–1.07) 0.38
  Patients who were suboptimally
  debulked after cytoreductive
  surgery
1114 784 0.94 (0.78–1.13) 0.50
  Post-menopausal patients > 52
  years
2226 1276 0.97 (0.84–1.12) 0.70
Progression-free survival
  All patients 3096 2144 1.01 (0.90–1.13) 0.84
  Patients who were suboptimally
  debulked after cytoreductive
  surgery
1114 961 1.03 (0.87–1.21) 0.74
  Post-menopausal patients >52
  years
2226 1603 1.02 (0.90–1.16) 0.76
Breast cancer
Overall survival
  All patients 28,471 3013 0.96 (0.87–1.06) 0.38
  ER-positive patients 20,071 1754 0.96 (0.85–1.10) 0.58
  ER-negative patients 4778 771 0.97 (0.81–1.18) 0.78
Breast cancer-specific survival
  All patients 28,471 1693 0.95 (0.83–1.08) 0.40
Overall survival
  BRCA1 mutation carriers 1706 241 0.72 (0.48–1.08) 0.11
  BRCA2 mutation carriers 917 162 0.98 (0.65–1.46) 0.90
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